Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.53 |
| ▸ | CES1 | P23141 | 2/20 | 0.53 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MLYCD | O95822 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29729945 | 1.00 | CES2 (0.53) | CES2CES1TRPM8PARP1OPRM1 | |
| SCHEMBL14784157 | 0.91 | TRPM8 (0.56) | CES2CES1TRPM8OPRM1OPRL1 | |
| SCHEMBL30678242 | 0.88 | NPC1 (0.49) | CES2CES1TRPM8OPRM1OPRL1 | |
| SCHEMBL15281239 | 0.87 | KMT2A (0.50) | CES2CES1TRPM8PARP1TSHR | |
| SCHEMBL906184 | 0.84 | CES2 (0.55) | CES2CES1PARP1OPRM1OPRL1 | |
| SCHEMBL16214051 | 0.82 | MEN1 (0.46) | CES2CES1ALDH1A1MEN1KMT2A | |
| SCHEMBL255000 | 0.82 | CES2 (0.61) | CES2CES1PARP1OPRM1OPRL1 | |
| SCHEMBL3651911 | 0.82 | MLYCD (0.47) | CES2CES1TRPM8NPC1RAB9A | |
| SCHEMBL29482201 | 0.82 | CES2 (0.61) | CES2CES1PARP1OPRM1OPRL1 | |
| SCHEMBL2652369 | 0.81 | HPGD (0.57) | PARP1NPC1RAB9AHDAC6MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534457-B2 | Heteroaryl derivative compounds, and uses thereof | VORONOI INC. (KR) | 2026-01-27 | — | — | US | disclosed |
| US-12528799-B2 | Heteroaryl derivative compounds, and uses thereof | VORONOI INC. (KR) | 2026-01-20 | — | — | US | disclosed |
| US-20250368635-A1 | HETEROARYL DERIVATIVE COMPOUND, AND USES THEREOF | VORONOI, INC. (KR) | 2025-12-04 | — | — | US | disclosed |
| EP-4631507-A2 | HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT | Voronoi Inc. (KR) | 2025-10-15 | — | — | EP | disclosed |
| EP-4619403-A1 | HETEROARYL DERIVATIVE COMPOUND, AND USES THEREOF | Voronoi, Inc. (KR) | 2025-09-24 | — | — | EP | disclosed |
| EP-3943491-B1 | HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT | VORONOI INC (KR) | 2025-06-18 | — | — | EP | disclosed |
| US-20250019373-A1 | ARYL OR HETEROARYL DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF KINASE-RELATED DISEASES | VORONOI INC. (KR) | 2025-01-16 | — | — | US | disclosed |
| US-12157730-B2 | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component | VORONOI INC. (KR) | 2024-12-03 | — | — | US | disclosed |
| US-12152021-B2 | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component | VORONOI INC. (KR) | 2024-11-26 | — | — | US | disclosed |
| US-20240317730-A1 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | VORONOI INC. (KR) | 2024-09-26 | — | — | US | disclosed |
| WO-2004052868-A1 | PYRAZINE-BASED TUBULIN INHIBITORS | CYTOPIA PTY LTD (AU) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004043458-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20040092521-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES | 2004-05-13 | — | — | US | disclosed |
| EP-1115729-A1 | PHOSPHONIC ACID DERIVATIVES AS INHIBITORS OF PTP-1B | Merck Frosst Canada & Co. (CA) | 2001-07-18 | — | — | EP | disclosed |
| US-6174874-B1 | ANTIDIABETIC,-CARCINOGENIC AGENTS; IMPROVING GLUCOSE TOLERANCE/INSULIN-SENSITIVITY; PREVENTING/TREATING OBESITY AND NEURODEGENERATIVE DISEASES; E.G. 1,3-BIS-((PHOSPHONODI-FLUOROMETHYL)PHENYL)-2-DICARBOXYPROPANE | MERCK FROSST CANADA & CO. (CA) | 2001-01-16 | — | — | US | disclosed |
| EP-1031572-A1 | PYRIDYLPYRROLE DERIVATIVES | Sankyo Company Limited (JP) | 2000-08-30 | — | — | EP | disclosed |
| WO-2000017211-A1 | PHOSPHONIC ACIDS DERIVATIVES AS INHIBITORS OF PTP-1B | MERCK FROSST CANADA & CO. (CA) | 2000-03-30 | — | — | WO | disclosed |
| US-5494918-A | ANTICHOLESTEROL AGENTS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-02-27 | — | — | US | disclosed |
| US-5385912-A | Hypocholesterolemic or hypolipidemic agents | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-01-31 | — | — | US | disclosed |
| WO-1992015579-A1 | MULTICYCLIC TERTIARY AMINE POLYAROMATIC SQUALENE SYNTHETASE INHIBITORS | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12157730-B2 | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component | ERBB4, ERBB2, EGFR | CES2 3680/4885CES1 3409/4885TRPM8 2466/4885 |
| US-20250368635-A1 | HETEROARYL DERIVATIVE COMPOUND, AND USES THEREOF | ERBB2, EGFR, ERBB3 | CES2 2512/4885CES1 3354/4885TRPM8 2519/4885 |
| US-12152021-B2 | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component | ERBB4, ERBB2, EGFR | CES2 3680/4885CES1 3409/4885TRPM8 2466/4885 |
| US-20240317730-A1 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | ERBB2, EGFR, ERBB3 | CES2 2857/4885CES1 3727/4885TRPM8 3409/4885 |
| US-12528799-B2 | Heteroaryl derivative compounds, and uses thereof | ERBB2, EGFR, ERBB3 | CES2 1116/4885CES1 706/4885TRPM8 2503/4885 |
| US-12534457-B2 | Heteroaryl derivative compounds, and uses thereof | ERBB2, EGFR, ERBB3 | CES2 1186/4885CES1 807/4885TRPM8 856/4885 |
| US-20040092521-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | HRH3, HRH4, HRH1 | CES2 1258/4885CES1 827/4885TRPM8 377/4885 |
| US-20250019373-A1 | ARYL OR HETEROARYL DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF KINASE-RELATED DISEASES | RIPK1, RIPK2, RIPK3 | CES2 3920/4885CES1 1421/4885TRPM8 2983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.